rhG-CSF对小儿化疗所致的白细胞缺乏症的临床观察

本文报告１９９４．２～１９９５．３我们用ｒｈＧ－ＣＳＦ（惠尔血．ＧＲＡＮ）对１９例儿童肿瘤进行了３０例次在化疗后出现粒细胞缺乏症时的临床观察。有自身前后疗程对照１３例（１９例次），前后疗程化疗方案完全相同。每例前１疗程单用化疗为对照疗程，后一疗程在化疗结束后，当ｗｂｃ＜２．０×１０９／Ｌ或ＡＮＣ＜０．５×１０９／Ｌ时使用惠尔血７５ｍｃｇ，每日１次，皮下注射。一般用３～５天，ｗｂｃ及ＡＮＣ即可达到临床要求标准（ｗｂｃ≥４．０×１０９／Ｌ，ＡＮＣ≥１．５×１０９／Ｌ）。试验疗程较对照疗程粒细胞恢复时间明显缩短（ｗｂｃ提前９．３天恢复），ＡＮＣ提前８天恢复。在６例患儿化疗后用惠尔血（１１例次）未设自身对照疗程，临床观察亦获得与上述相似的疗效。本组在３０例次中仅见２例次有发热和骨痛，停药后发热和骨痛消失，未见其它不良反应。观察结果显示，惠尔血对小儿肿瘤化疗所致的粒细胞缺乏症疗效肯定。我们采用在停化疗后ｗｂｃ＜２．０×１０９／Ｌ几或ＡＮＣ＜０．５×１０９／Ｌ时开始使用惠尔血７５ｍｃｇ，１／日，皮下注射。一般３天至５天即可达到预期效果。用药量小，毒副作用少，既能减轻患儿痛苦，又能减轻家庭经济负担．是一种适合国情的用药方

CLINICAL OBSERVATION ON THE EFFECT OF rhG-CSF FOR LEUKOCYTOPENIA POST-CHEMOTHERAPY OF PATIENTS OF CHILDREN MALIGNANT DISEASES

Abstract:19 children with leukocytopenia post-chemotherapy of malignant diseases received rhGCSF (Filgrastim, Gran). 13 patients were taken self-control in it. In experimental course oftreatment, they were given rhG-CSF 75 mcg/d when WBC<2'.0 × 109/L or ANC<0.05 ×109/L. Generally,WBC and ANC reached the clinical standard(WBC≥4.0 × 109/L,ANC≥1'.5 × 109/L)for 3-5 days after using the drug. The recovery time for WBC and ANC in experimental course of treatment earlier than in control course of treatment. The recovery ofWBC and ANC were 9. 3 days and 8. 0 days ahead of time, respectively. In addition, 6 caseswere not taken self-control. The results were similar to the above. 2/19 cases had fever andbone ache. They disappeared after stopping the drug. In a word, rhG--GSF is effective fortreating leukocytoperiia post-chemotherapy.